We identified five prognostic markers for RCC that are also expressed in BMDM (DUSP22, MAPK14, MAPKAPK3, STAT1, and VCP) and DUSP22 as a regulator of RCC metastasis and novel target for drug development. Here, DUSP22 is linked to renal cell adenocarcinoma.